XRAY Stock Recent News
XRAY LATEST HEADLINES
Investors need to pay close attention to XRAY stock based on the movements in the options market lately.
XRAY continues to gain traction from a robust product portfolio. However, the macroeconomic factors, such as weakened global demand, persist.
NEW YORK CITY, NY / ACCESS Newswire / June 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dentsply Sirona Inc. ("Dentsply" or "the Company") (NASDAQ:XRAY). Investors who purchased Dentsply securities prior to May 6, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/XRAY.
PHILADELPHIA, PA / ACCESS Newswire / June 9, 2025 / Kaskela Law LLC announces that it is investigating potential breach of fiduciary duty claims concerning Dentsply Sirona Inc. (NASDAQ:XRAY) ("Dentsply") on behalf of the company's long-term investors. Click here to receive additional information about your legal rights and options: https://kaskelalaw.com/case/dentsply-sirona/ Recently an amended securities fraud complaint was filed against Dentsply on behalf of investors who purchased shares of the company's stock between June 9, 2021 and November 13, 2022.
NEW YORK CITY, NY / ACCESS Newswire / June 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dentsply Sirona Inc. ("Dentsply" or "the Company") (NASDAQ:XRAY). Investors who purchased Dentsply securities prior to May 6, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/XRAY.
CHARLOTTE, N.C., June 05, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the “Company”) (Nasdaq: XRAY) today announced it has priced an offering (the “Offering”) of $550 million aggregate principal amount of its 8.375% Junior Subordinated Notes due 2055 (the “notes”).
NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dentsply Sirona Inc. ("Dentsply" or "the Company") (NASDAQ:XRAY). Investors who purchased Dentsply securities prior to May 6, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/XRAY.
I'm changing my tune on XRAY and buying at current levels due to its cheap valuation and attractive risk premium over Treasuries. Despite sluggish recent financials, the balance sheet is solid with ample cash and a sustainable dividend, making the stock less risky now. Key headwinds are likely fading, and an aging population could provide a tailwind for future growth, supporting a speculative buy.
NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dentsply Sirona Inc. ("Dentsply" or "the Company") (NASDAQ:XRAY). Investors who purchased Dentsply securities prior to May 6, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/XRAY.
NEW YORK CITY, NY / ACCESS Newswire / June 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dentsply Sirona Inc. ("Dentsply" or "the Company") (NASDAQ:XRAY). Investors who purchased Dentsply securities prior to May 6, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/XRAY.